Cancer Res Treat.  2016 Oct;48(4):1286-1292. 10.4143/crt.2016.018.

Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08

• Kim KH
• Kim JH
• Lee JY
• Kim HS
• Heo SJ
• Kim JH
• Kim HY
• Rha SY

• KMID: 2356230
• DOI: http://doi.org/10.4143/crt.2016.018

Abstract

PURPOSE
We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis.
MATERIALS AND METHODS
Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment.
RESULTS
Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m². The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level.
CONCLUSION
Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.

Keyword

TOR serine-threonine kinases; Renal cell carcinoma; Renal insufficiency

MeSH Terms

Anorexia
Carcinoma, Renal Cell*
Creatinine
Dialysis
Disease-Free Survival
Everolimus
Fatigue
Glomerular Filtration Rate
Humans
Renal Insufficiency*
Renal Insufficiency, Chronic
Sirolimus*
Stomatitis
TOR Serine-Threonine Kinases
Creatinine
Everolimus
Sirolimus
TOR Serine-Threonine Kinases

Figure

• 

  Fig. 1. Kaplan-Meier estimates of progression-free survival (A) and overall survival (B) durations in patients treated with mammalian target rapamycin inhibitors as a second-line treatment (n=18). (A) Median progression-free survival: 4 months (95% confidence interval [CI], 1.1 to 6.9). (B) Median overall survival: 18 months (95% CI, 6.9 to 29.1).

Reference

References

1. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26:5422–8.

2. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372:449–56.

3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356:2271–81.

4. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014; 32:760–7.

5. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28:1061–8.

6. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356:125–34.

7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27:3584–90.

8. Oudard S, Medioni J, Aylllon J, Barrascourt E, Elaidi RT, Balcaceres J, et al. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2009; 9:705–17.

9. Iacovelli R, Palazzo A, Trenta P, Mezi S, Pellegrino D, Naso G, et al. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. Am J Clin Oncol. 2014; 37:611–5.

10. Woldu SL, Weinberg AC, RoyChoudhury A, Chase H, Kalloo SD, McKiernan JM, et al. Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology. Int Urol Nephrol. 2014; 46:2127–32.

11. Hofmann JN, Purdue MP. CKD and risk of renal cell carcinoma: a causal association? J Am Soc Nephrol. 2014; 25:2147–8.

12. Russo P. End stage and chronic kidney disease: associations with renal cancer. Front Oncol. 2012; 2:28.

13. Chang A, Finelli A, Berns JS, Rosner M. Chronic kidney disease in patients with renal cell carcinoma. Adv Chronic Kidney Dis. 2014; 21:91–5.

14. Shetty AV, Matrana MR, Atkinson BJ, Flaherty AL, Jonasch E, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clin Genitourin Cancer. 2014; 12:348–53.

15. Neuzillet Y, Tillou X, Mathieu R, Long JA, Gigante M, Paparel P, et al. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol. 2011; 60:366–73.

16. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando). 2008; 22:125–30.

17. Simpson D, Curran MP. Temsirolimus: in advanced renal cell carcinoma. Drugs. 2008; 68:631–8.

18. Kovarik JM, Sabia HD, Figueiredo J, Zimmermann H, Reynolds C, Dilzer SC, et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther. 2001; 70:425–30.

19. Kim KH, Kim HY, Kim HR, Sun JM, Lim HY, Lee HJ, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. Eur J Cancer. 2014; 50:746–52.